A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes towards the controversial approach.
Investigators at Weill Cornell Medicine have developed a versatile and non-toxic technology for controlling the activity of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback